10 September 2018 ORYZON receives approval to start ALICE: a Phase IIa clinical trial in AML with Iadademstat (ORY-1001)
7 September 2018 Oryzon receives approval to begin REIMAGINE: a Phase IIa clinical trial with Vafidemstat (ORY-2001) in aggressiveness
30 July 2018 ORYZON Reports Financial Results and Corporate Update for the 1st Half Ended June 30, 2018
25 June 2018 ORYZON announces First Patients in the UK in ETHERAL: a Phase IIa clinical trial in Alzheimer’s Disease with ORY-2001
30 May 2018 Oryzon Genomics reaffirms its commitment to the research in neurodegenerative diseases on the World Multiple Sclerosis Day